These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 24073461)
61. Keeping communities at the centre of efforts to eliminate lymphatic filariasis: learning from the past to reach a future free of lymphatic filariasis. Krentel A; Gyapong M; McFarland DA; Ogundahunsi O; Titaley CR; Addiss DG Int Health; 2020 Dec; 13(Supplement_1):S55-S59. PubMed ID: 33349882 [TBL] [Abstract][Full Text] [Related]
65. A campaign of "communication for behavioural impact" to improve mass drug administrations against lymphatic filariasis: structure, implementation and impact on people's knowledge and treatment coverage. Ramaiah KD; Vijay Kumar KN; Hosein E; Krishnamoorthy P; Augustin DJ; Snehalatha KS; Nanda B; Das PK Ann Trop Med Parasitol; 2006 Jun; 100(4):345-61. PubMed ID: 16762115 [TBL] [Abstract][Full Text] [Related]
66. The global programme to eliminate lymphatic filariasis. Ottesen EA Trop Med Int Health; 2000 Sep; 5(9):591-4. PubMed ID: 11044272 [TBL] [Abstract][Full Text] [Related]
67. India tackles lymphatic filariasis. Bagcchi S Lancet Infect Dis; 2015 Apr; 15(4):380. PubMed ID: 25809895 [TBL] [Abstract][Full Text] [Related]
69. Impact of mass drug administration on elimination of lymphatic filariasis in Surat city, India. Vaishnav KG; Desai HS; Srivastava PK; Joshi PT; Kurian G; Thakor HG; Dhariwal AC J Commun Dis; 2012 Dec; 44(4):251-9. PubMed ID: 25145075 [TBL] [Abstract][Full Text] [Related]
70. An Ensemble Framework for Projecting the Impact of Lymphatic Filariasis Interventions Across Sub-Saharan Africa at a Fine Spatial Scale. Touloupou P; Fronterre C; Cano J; Prada JM; Smith M; Kontoroupis P; Brown P; Rivera RC; de Vlas SJ; Gunawardena S; Irvine MA; Njenga SM; Reimer L; Seife F; Sharma S; Michael E; Stolk WA; Pulan R; Spencer SEF; Hollingsworth TD Clin Infect Dis; 2024 Apr; 78(Supplement_2):S108-S116. PubMed ID: 38662704 [TBL] [Abstract][Full Text] [Related]
71. Report on active surveillance for adverse events following the use of drug co-administrations in the global programme to eliminate lymphatic filariasis. Wkly Epidemiol Rec; 2003 Sep; 78(36):315-7. PubMed ID: 14518107 [No Abstract] [Full Text] [Related]
73. Seventh meeting of the Global Alliance to Eliminate Lymphatic Filariasis: reaching the vision by scaling up, scaling down, and reaching out. Brady M; Parasit Vectors; 2014 Jan; 7():46. PubMed ID: 24450283 [TBL] [Abstract][Full Text] [Related]
74. The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000-2014). Turner HC; Bettis AA; Chu BK; McFarland DA; Hooper PJ; Ottesen EA; Bradley MH Infect Dis Poverty; 2016 May; 5(1):54. PubMed ID: 27388873 [TBL] [Abstract][Full Text] [Related]
75. Reducing the population requiring interventions against lymphatic filariasis in Africa. Bockarie MJ; Rebollo MP Lancet Glob Health; 2016 Mar; 4(3):e154-5. PubMed ID: 26874545 [No Abstract] [Full Text] [Related]
76. Lymphatic filariasis: constraints ahead. Mishra CP; Singh N Indian J Public Health; 2003; 47(1):27-30. PubMed ID: 14723292 [No Abstract] [Full Text] [Related]
77. [ Bancroftian lymphatic filariasis: toward its elimination from the Pacific?]. Chanteau S; Roux JF Bull Soc Pathol Exot; 2008 Jun; 101(3):254-60. PubMed ID: 18681220 [TBL] [Abstract][Full Text] [Related]
78. Elimination of lymphatic filariasis as a public health problem. Cox FE Parasitol Today; 2000 Apr; 16(4):135. PubMed ID: 10725894 [No Abstract] [Full Text] [Related]
79. Current status and future prospects of the Global Lymphatic Filariasis Programme. Molyneux DH; Taylor MJ Curr Opin Infect Dis; 2001 Apr; 14(2):155-9. PubMed ID: 11979126 [TBL] [Abstract][Full Text] [Related]
80. The development of albendazole for lymphatic filariasis. Horton J Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S33-40. PubMed ID: 19843396 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]